GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency. The company is based in Edinburgh, United Kingdom.
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.03 | B | |
| $15.31 | C | |
| $4.38 | C |